Mesoblast Limited Share Price
Stocks
MSB
AU000000MSB8
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Australian S.E.
05:10:10 28/10/2026 GMT
|
5-day change | 1st Jan Change | ||
| 1.880 AUD | +1.35% |
|
+6.82% | -30.88% |
| 10-16 | Mesoblast Says Ryoncil Net Revenue Increased 44% Year Over Year in September Quarter; Shares Hit 52-Week Low | MT |
| 09-24 | Sector Update: Healthcare Stocks Advance Late Afternoon | MT |
| Market Cap | 2.41B 1.69B 1.52B 1.4B 1.27B 2.38B 161B 16.83B 6.69B 84.35B 6.36B 6.22B 267B | P/E 2027 * |
-78.6x | P/E 2028 * | 19.7x |
|---|---|---|---|---|---|
| Enterprise Value | 2.51B 1.77B 1.59B 1.46B 1.33B 2.48B 168B 17.56B 6.97B 87.99B 6.63B 6.49B 279B | EV / Sales 2027 * |
9.86x | EV / Sales 2028 * | 6.13x |
| Free-Float |
63.88% | Yield 2027 * |
-
| Yield 2028 * | - |
| Markets | Quality | ||
|---|---|---|---|
Australian S.E.
| MSB | Delayed | |
Tradegate
| LWB | Real-time | |
|
OTC Markets
| MEOBF | Delayed | |
|
Boerse Muenchen
| LWB | Real-time | |
|
Deutsche Boerse AG
| LWB | Delayed | |
|
Börse Stuttgart
| LWB | Delayed | |
|
Berne S.E.
| LWB | End-of-day quote |
Last Transcript: Mesoblast Limited
| 1 day | +1.35% | ||
| 1 week | +6.82% | ||
| Current month | -10.90% | ||
| 1 month | -12.96% | ||
| 3 months | -12.15% | ||
| 6 months | -12.15% | ||
| Current year | -30.88% |
| 1 week | 1.76 |  | 1.95 |
| 1 month | 1.74 | | 2.16 |
| Current year | 1.74 | | 3.31 |
| 1 year | 1.74 | | 3.31 |
| 3 years | 0.26 | | 3.37 |
| 5 years | 0.26 | | 3.37 |
| 10 years | 0.26 | | 5.7 |
| Manager | Title | Age | Since |
|---|---|---|---|
Silviu Itescu
CEO | Chief Executive Officer | 69 | 22/03/2011 |
James O'Brien
DFI | Director of Finance/CFO | 59 | 16/11/2025 |
Teresa Montagut
CTO | Chief Tech/Sci/R&D Officer | - | 10/03/2026 |
| Director | Title | Age | Since |
|---|---|---|---|
Silviu Itescu
BRD | Director/Board Member | 69 | 31/12/2006 |
Eric Rose
BRD | Director/Board Member | 75 | 14/04/2013 |
William Burns
BRD | Director/Board Member | 79 | 05/03/2014 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 19/08/26 | Free | Director | 875,000 | 0.0674% | ||
| 17/07/26 | Exercice | Founder | 1,885,334 | 0.1456% | ||
| 17/07/26 | Exercice | Founder | -1,885,334 | 0.1456% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.35% | +6.82% | -26.56% | +415.07% | 1.69B | |
| +0.65% | -3.56% | +33.53% | +60.50% | 63.48B | |
| +2.63% | +2.14% | +12.77% | +83.68% | 54.55B | |
| -0.80% | +1.03% | +10.49% | +102.25% | 53.59B | |
| +2.89% | +1.43% | +28.63% | +58.38% | 44.75B | |
| +2.56% | -2.95% | +18.37% | +100.98% | 41.62B | |
| +1.20% | -3.51% | +222.26% | +921.58% | 39.91B | |
| +0.64% | -3.85% | +11.71% | +45.57% | 32.47B | |
| +29.21% | +45.00% | +103.43% | +90.81% | 26.7B | |
| +3.72% | -7.45% | +24.25% | -2.99% | 23.36B | |
| Average | +4.35% | +0.16% | +43.89% | +187.58% | 38.21B | |
| Weighted average by Cap. | +3.40% | -0.26% | +47.02% | +162.30% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 255M 179M 161M 149M 135M 252M 17.02B 1.78B 707M 8.92B 673M 658M 28.29B | 416M 293M 263M 243M 220M 411M 27.8B 2.91B 1.16B 14.57B 1.1B 1.08B 46.21B |
| Net income | -26.28M -18.48M -16.59M -15.32M -13.89M -25.96M -1.76B -184M -72.92M -920M -69.37M -67.89M -2.92B | 105M 73.61M 66.07M 61M 55.32M 103M 6.99B 731M 290M 3.66B 276M 270M 11.62B |
| Net Debt | 104M 73.19M 65.69M 60.65M 55M 103M 6.95B 727M 289M 3.64B 275M 269M 11.56B | 143M 101M 90.32M 83.4M 75.63M 141M 9.56B 1B 397M 5.01B 378M 370M 15.89B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 28/10/26 | A$1.880 | +1.35% | 2,650,500 |
| 27/10/26 | A$1.855 | +3.92% | 3,071,957 |
| 26/10/26 | A$1.785 | +0.56% | 1,315,866 |
| 23/10/26 | A$1.775 | -3.01% | 2,164,966 |
| 22/10/26 | A$1.830 | -1.61% | 3,004,349 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- MSB Stock
Select your edition
All financial news and data tailored to specific country editions
